Tacrolimus Alternatives Compared
Tacrolimus | Humira (adalimumab) | Stelara (ustekinumab) |
|
---|
Tacrolimus | Humira (adalimumab) | Stelara (ustekinumab) |
|
|||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Prescription only
Prescribed for Organ Transplant - Rejection Reversal, Organ Transplant - Rejection Prophylaxis, Graft Versus Host Disease, Crohn's Disease, Nephrotic Syndrome. Tacrolimus may also be used for... View more |
Prescription only
Humira is a TNF-alfa inhibitor that may be used to treat a wide range of different inflammatory conditions, such as Rheumatoid Arthritis, psoriasis, ankylosing spondylitis, Crohn's disease, and... View more |
Prescription only
Stelara is an immunosuppressant medication that works by binding to two inflammatory cytokines, IL-12 and IL-23, which have been identified as important contributors to chronic inflammation. Stelara... View more |
Related suggestions |
|||||||||||||||||||||||
More about Tacrolimus | More about Humira (adalimumab) | More about Stelara (ustekinumab) | ||||||||||||||||||||||||
Ratings & Reviews | ||||||||||||||||||||||||||
Tacrolimus has an average rating of 7.7 out of 10 from a total of 50 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 14% reported a negative effect. |
Humira has an average rating of 6.4 out of 10 from a total of 704 ratings on Drugs.com. 55% of reviewers reported a positive effect, while 30% reported a negative effect. |
Stelara has an average rating of 7.6 out of 10 from a total of 253 ratings on Drugs.com. 70% of reviewers reported a positive effect, while 15% reported a negative effect. |
||||||||||||||||||||||||
Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Tacrolimus side effects |
View all Humira side effects |
View all Stelara side effects |
||||||||||||||||||||||||
Drug Class | ||||||||||||||||||||||||||
Generic Availability | ||||||||||||||||||||||||||
Lower cost generic |
N/A |
N/A |
||||||||||||||||||||||||
Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Tacrolimus prices |
View all Humira prices |
View all Stelara prices |
||||||||||||||||||||||||
Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
Brand Names | ||||||||||||||||||||||||||
Astagraf XL, Envarsus XR, Prograf | Other adalimumab brands include: Abrilada, Amjevita, Cyltezo, Hadlima, Hulio, Hyrimoz, Idacio, Simlandi, Yuflyma, Yusimry View more | Other ustekinumab brands include: Imuldosa, Otulfi, Pyzchiva, Selarsdi, Starjemza, Steqeyma, Wezlana, Yesintek | ||||||||||||||||||||||||
Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
21.2 hours |
480 hours |
1291.2 hours |
||||||||||||||||||||||||
CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
Pregnancy Category | ||||||||||||||||||||||||||
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
Drug Interactions | ||||||||||||||||||||||||||
A total of 879 drugs are known to interact with Tacrolimus:
|
A total of 556 drugs are known to interact with Humira:
|
A total of 542 drugs are known to interact with Stelara:
|
||||||||||||||||||||||||
Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
Disease Interactions | ||||||||||||||||||||||||||
First Approval Date | ||||||||||||||||||||||||||
April 08, 1994 |
December 31, 2002 |
September 25, 2009 |
||||||||||||||||||||||||
WADA Class View classifications | ||||||||||||||||||||||||||
N/A |
N/A |
N/A |
||||||||||||||||||||||||
More Information | ||||||||||||||||||||||||||
Patient Resources | ||||||||||||||||||||||||||
Professional Resources | ||||||||||||||||||||||||||
Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
See also:
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.